Skip to main content

Table 3 AT Outcome Table

From: Potential biological therapies for severe preeclampsia: a systematic review and meta-analysis

Reference

Population

Dose

Blood pressure (mmHg)

Proteinuria (g/day)

Gestational age at delivery (weeks)

Pregnancy prolongation (days)

 

AT

Control

AT

Control

AT

Control

AT

Control

AT

Control

D’Angelo, 2016 [22]

Pregnant women diagnosed with PE before 30WG (n = 38)

3000 IU/daily of AT for 7 days or less until delivery

Placebo, 1% glycine, for 7 days or less until delivery

  

Diagnosis: 2.28 ± 2.31 Pre-partum:4.02 ± 3.60

Diagnosis: 2.31 ± 1.68 Pre-partum: 4.58 ± 4.28

  

Median: 4.5 Range: 1–55

Median:3.5 Range: 1–57

Maki, 2000 [20]

Pregnant women diagnosed with PE between 24WG and 35WG (n = 133)

3000 IU/daily of AT for 7 days or less until delivery

Placebo, 582 mg human albumin, once daily for 7 days

    

34.1 ± 3.2**

33.0 ± 2.7

Prolonged gestation by 6.5 compared to placebo **

N/A

Sameshima, 2008 [9]

Pregnant women diagnosed with PE before 32WG (n = 82)

3000 IU/daily of AT for 7 days or less until delivery

Placebo, 582 mg human albumin, once daily for 7 days

    

24–27: n = 5 28–29: n = 2 30–31: n = 11 32–33: n = 10 34≤: n = 11* (compared to control at 34≤)

24–27: n = 1, 28–29: n = 11 30–31: n = 9 32–33: n = 16 34≤: n = 4

  

Sibai, 2017 [23]

Pregnant women diagnosed with PE between 23WG and 30WG (n = 120)

rhAT 250 mg loading dose followed by a continuous infusion 2000 mg/24 h

Placebo, identical to AT dose except with saline

    

28.8 ± 2.7

 

11.2 ± 14.6

16.1 ± 20.9

Paternoster, 2007 [25]

Pregnant women diagnosed with PE between 24WG and 30WG (n = 88)

5000 IU on day 1, then received a dose that was calibrated to achieve a plasma level of a minimum of 120% of baseline value for the next 6 days.

Placebo

      

Unknown. States that pregnancy was prolonged in AT group.

N/A

Paternoster, 2004 [24]

Pregnant women diagnosed with PE between 24 and 33WG (n = 23)

Received one dose of AT sufficient to reach a plasma AT activity of at least 80% of the normal as well as 3000 U/day for 5 days

One dose of AT sufficient to reach a plasma AT activity of at least 80% of the normal

  

Baseline: 1.56 Change: 5.14

Baseline: 3.07 Change: 2.85

28.76 ± 3.83

29.35 ± 3.10

6 ± 2.1

3.5 ± 3.4

Nakabayashi, 1999 [26]

Pregnant women with PE before 32WG (n = 29)

1500 U/day of AT concentrate plus 5000 U/day of heparin was administered intravenously for 7 days

5000 U/day of heparin for 7 days

Systolic: 145.3 ± 3.2** Diastolic: 110.3 ± 4.9

Systolic: 161.4 ± 2.9 Diastolic: 106.1 ± 4.5

  

32.1 ± 2.5

31.8 ± 2.3

  

Kobayashi, 2003 [21]

Pregnant women diagnosed with PE between 24WG and 36WG (n = 29)

1500 U/day of AT concentrate plus 5000 U/day of heparin was administered intravenously for 7 days

5000 U/day of heparin for 7 days

    

32.3 ± 3.1

29.8 ± 3.7

  

Shinyama, 1996 [28]

Pregnant rats fed high salt diet (n = 36)

Low dose group: 60 U/kg/day for 10 days; High dose group: 300

Placebo, 3 mL/kg/day of saline for 10 days

High dose: 233*; Low dose: 236

At 15–17 DG: 249mmHg

High (300 U/kg/day): 32*; Low (60 U/kg/day): 51

At 17–19 DG: 93.5 (mg/kg/24h)

    
  1. DG day of gestation, WG week of gestation
  2. *statistically significant at p < 0.05
  3. **statistically significant at p < 0.01